DS-3201b in Participants With Lymphomas
Active, not recruiting · Phase 1 · NCT02732275
Conditions: Lymphoma, Malignant, Non-hodgkin Lymphoma
At a glance
- Research payments reported, 2025
- $275,418
- U.S. investigators named
- 8
- Sites paid
- 9
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- Daiichi Sankyo Co., Ltd. (with Daiichi Sankyo)
- Tested
- DS-3201b (drug), DS-3201b (drug)
- Dates
- Started 2016-03-31; completion 2027-12-31
- Results posted
- Not yet
DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment This study has three parts. The Dose Escalation part is designed is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. The Dose Expansion phase will determine how effective DS-3201b is for rare types of NH and collect additional safety data. Last, the Drug-Drug Interaction (DDI) Cohort (US Only) will evaluate the effect of DS-3201b on the pharmacokinetics (PK) of midazolam and digoxin when co-administered to patients with NHL
From ClinicalTrials.gov, last updated 2026-04-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $275,418 in research payments for this study in 2025 (54 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Francine M. Foss, MD Medical Oncology · New Haven, CT
- Eric D. Jacobsen, MD Hematology & Oncology · Boston, MA
- Tatyana A. Feldman, M.D. Medical Oncology · Hackensack, NJ
- Steven Horwitz, MD Medical Oncology · New York, NY
- Jia Ruan, MD, PHD Medical Oncology · New York, NY
- Jonathan E. Brammer, MD Hematology · Columbus, OH
- Pierluigi Porcu, M.D. Hematology & Oncology · Philadelphia, PA
- Jie Wang, MD Hematology & Oncology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $125,697
- Duke University $43,264
- Weill Medical College of Cornell University $27,072
- Thomas Jefferson University Hospital, PA $21,101
- Memorial Hospital for Cancer and All $15,128
- Dana-Farber Cancer Institute $13,205
- Hackensack University Medical Center, NJ $10,907
- Yale University $10,388
- Ohio State University $8,656
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.